[go: up one dir, main page]

MX9404999A - Aislamiento y estructura de las espongistatinas 5,7, 8 y 9. - Google Patents

Aislamiento y estructura de las espongistatinas 5,7, 8 y 9.

Info

Publication number
MX9404999A
MX9404999A MX9404999A MX9404999A MX9404999A MX 9404999 A MX9404999 A MX 9404999A MX 9404999 A MX9404999 A MX 9404999A MX 9404999 A MX9404999 A MX 9404999A MX 9404999 A MX9404999 A MX 9404999A
Authority
MX
Mexico
Prior art keywords
spongistatin
spongistin
found
human cancer
spongistatines
Prior art date
Application number
MX9404999A
Other languages
English (en)
Inventor
George R Pettit
Zbigniew A Cichacz
Cherry L Herald
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of MX9404999A publication Critical patent/MX9404999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una esponja marina del Océano Indico SubOeste SpirastrellaSpinispirulifera (colores rojos y púrpura brillantes) se ha encontrado quecontiene inhibidores de crecimiento de células nuevas y excepcionalmenteactivas (cáncer humano) espongistina 5, espongistina 7, espongistatina 8 yespongistatina 9. Estas composiciones están relacionadas con laespongistatina 1, que se encontró en Spongia sp. negra en la familiaPorifera. Se da asimismo a conocer un método para tratar células de cáncerhumano con espongistatina 5 y espongistatina 7.
MX9404999A 1993-07-02 1994-06-30 Aislamiento y estructura de las espongistatinas 5,7, 8 y 9. MX9404999A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/086,664 US5393897A (en) 1993-07-02 1993-07-02 Isolation and structure of spongistatins 5,7,8 and 9

Publications (1)

Publication Number Publication Date
MX9404999A true MX9404999A (es) 1995-01-31

Family

ID=22200068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9404999A MX9404999A (es) 1993-07-02 1994-06-30 Aislamiento y estructura de las espongistatinas 5,7, 8 y 9.

Country Status (9)

Country Link
US (1) US5393897A (es)
EP (1) EP0634414B1 (es)
JP (1) JP3430322B2 (es)
AT (1) ATE169919T1 (es)
CA (1) CA2126910C (es)
DE (1) DE69412551T2 (es)
DK (1) DK0634414T3 (es)
ES (1) ES2123714T3 (es)
MX (1) MX9404999A (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048278A1 (en) * 1996-06-18 1997-12-24 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of The Arizona State University Antifungal activity of the spongistatins
US5883120A (en) * 1997-06-16 1999-03-16 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Antifungal activity of the spongistatins
US5952376A (en) * 1997-11-07 1999-09-14 The Trustees Of The University Of Pennsylvania Trienyl compounds
US6521661B1 (en) 2000-07-20 2003-02-18 Harbor Branch Oceanographic Institution, Inc. Cyclic peroxides as novel antifungal agents
DE60229371D1 (de) * 2001-05-02 2008-11-27 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
TW201206425A (en) * 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
KR101347100B1 (ko) 2005-07-29 2014-01-03 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
CN101541322A (zh) 2006-07-28 2009-09-23 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
CN101848726A (zh) 2007-02-09 2010-09-29 布朗歇特洛克菲勒神经科学研究所 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
CA3006091A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
US9053844B2 (en) * 2009-09-09 2015-06-09 Littelfuse, Inc. Geometric configuration or alignment of protective material in a gap structure for electrical devices
US20120020948A1 (en) 2010-07-08 2012-01-26 Alkon Daniel L Dag-type and indirect protein kinase c activators and anticoagulant for the treatment of stroke
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
EP3294290A1 (en) 2015-05-11 2018-03-21 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164584A (en) * 1977-10-25 1979-08-14 Research Corporation Anti-leukemic trichothecene epoxides
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US4996229A (en) * 1985-06-06 1991-02-26 University Of Hawaii Scytophycins
EP0216731B1 (de) * 1985-09-13 1990-03-14 Gesellschaft für Biotechnologische Forschung mbH (GBF) Makrozyklische Antibiotika
US4833257A (en) * 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
US4940726A (en) * 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
US5436400A (en) * 1993-01-19 1995-07-25 Arizona Board Of Regents Isolation and structure of spongistatin 1
US5328929A (en) * 1993-07-02 1994-07-12 Arizona Board Of Regents Isolation and structure of spongistatin 2, spongistatin 3, spongistatin 4 and spongistatin 6

Also Published As

Publication number Publication date
JP3430322B2 (ja) 2003-07-28
DE69412551D1 (de) 1998-09-24
CA2126910C (en) 2001-07-17
ATE169919T1 (de) 1998-09-15
EP0634414B1 (en) 1998-08-19
US5393897A (en) 1995-02-28
JPH07157428A (ja) 1995-06-20
EP0634414A1 (en) 1995-01-18
CA2126910A1 (en) 1995-01-03
DK0634414T3 (da) 1999-05-25
DE69412551T2 (de) 1999-02-04
ES2123714T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
MX9404999A (es) Aislamiento y estructura de las espongistatinas 5,7, 8 y 9.
AU4057897A (en) Lip treatment containing live yeast cell derivative
JPS57500830A (es)
EA199900486A1 (ru) Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
NO972171L (no) Regulering av neural stamcelleproliferasjon
IT1113410B (it) Procedimento per produrre idrogeno e ossigeno,nonche' cella elettrolitica per attuare tale procedimento
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ATE35695T1 (de) Mikrobielle polysaccharide, verfahren zu ihrer herstellung, dafuer geeignete mikroorganismen und verwendung der polysaccharide.
AU1116400A (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
ATE215135T1 (de) Verfahren zur herstellung von solvens- stabilisierten metallkolloiden und trägerfixierten metallclustern
ATE336488T1 (de) Neue ortho-naphthochinonderivate, neue synthesen zu ihrer herstellung und ihre anwendung in der inhibierung von neoplastischem zellwachstum
ES2172690T3 (es) Compuestos de mercaptoalquilpeptidil con un sustituyente de imidazol y su utilizacion como inhibidores de metaloproteinasas de matriz (mmp) y/o del factor de necrosis tumoral (tnf).
MX9405002A (es) Aislamiento y estructura de espongistatina 2, espongistatina 3,espongistatina 4 y espongistatina 6.
ZA961973B (en) Sertoli cells as transplantation facilitator for cell transplantation
KR970064396A (ko) 스트레스 완화용 사료
MD909G2 (ro) Procedeu de obţinere a biomasei de alge roşii Porphyridium cruentum
IT8023442V0 (it) Procedimento per la produzione elettrolitica di idrogeno e cella elettrolitica adatta per questo scopo.
KR870001762A (ko) 냄새가 없는 대두(大豆) 신품종의 생산방법
GB1436573A (en) Microorganisms
DE69520829D1 (de) Herstellung von L - Ascorbinsäure in Mikroorganismen
BR9904948A (pt) Processo para a produção fermentativa de l-aminoácidos.
JPS53113025A (en) Proliferation inhibitor for microorganisms
Pfeiler et al. Glycosaminoglycan composition of tarpon (Megalops atlanticus) and ladyfish (Elops saurus) leptocephali
JPS5353143A (en) Method of plant construction
KR890016124A (ko) 메이컵 화장품용 안료 처리방법